nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirtazapine—HRH3—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0479	0.0479	CbGpPWpGaD
Mirtazapine—HRH3—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0381	0.0381	CbGpPWpGaD
Mirtazapine—OPRK1—Peptide ligand-binding receptors—CXCL11—nasal cavity cancer	0.0298	0.0298	CbGpPWpGaD
Mirtazapine—HRH3—GPCR ligand binding—CXCL11—nasal cavity cancer	0.029	0.029	CbGpPWpGaD
Mirtazapine—OPRK1—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0251	0.0251	CbGpPWpGaD
Mirtazapine—DRD4—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0237	0.0237	CbGpPWpGaD
Mirtazapine—DRD3—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.021	0.021	CbGpPWpGaD
Mirtazapine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.02	0.02	CbGpPWpGaD
Mirtazapine—HTR7—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0197	0.0197	CbGpPWpGaD
Mirtazapine—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0188	0.0188	CbGpPWpGaD
Mirtazapine—HTR1A—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0183	0.0183	CbGpPWpGaD
Mirtazapine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.018	0.018	CbGpPWpGaD
Mirtazapine—ADRA2C—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0177	0.0177	CbGpPWpGaD
Mirtazapine—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0167	0.0167	CbGpPWpGaD
Mirtazapine—HRH3—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0164	0.0164	CbGpPWpGaD
Mirtazapine—DRD2—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0161	0.0161	CbGpPWpGaD
Mirtazapine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0152	0.0152	CbGpPWpGaD
Mirtazapine—OPRK1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0152	0.0152	CbGpPWpGaD
Mirtazapine—HTR7—GPCR ligand binding—CXCL11—nasal cavity cancer	0.015	0.015	CbGpPWpGaD
Mirtazapine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0149	0.0149	CbGpPWpGaD
Mirtazapine—HRH3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0149	0.0149	CbGpPWpGaD
Mirtazapine—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0146	0.0146	CbGpPWpGaD
Mirtazapine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0145	0.0145	CbGpPWpGaD
Mirtazapine—ADRA2A—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0144	0.0144	CbGpPWpGaD
Mirtazapine—DRD4—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0143	0.0143	CbGpPWpGaD
Mirtazapine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0141	0.0141	CbGpPWpGaD
Mirtazapine—HTR2B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0137	0.0137	CbGpPWpGaD
Mirtazapine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0128	0.0128	CbGpPWpGaD
Mirtazapine—DRD3—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0127	0.0127	CbGpPWpGaD
Mirtazapine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0126	0.0126	CbGpPWpGaD
Mirtazapine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0126	0.0126	CbGpPWpGaD
Mirtazapine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0123	0.0123	CbGpPWpGaD
Mirtazapine—ADRB1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0116	0.0116	CbGpPWpGaD
Mirtazapine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0115	0.0115	CbGpPWpGaD
Mirtazapine—ADRB2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0114	0.0114	CbGpPWpGaD
Mirtazapine—HTR1A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0111	0.0111	CbGpPWpGaD
Mirtazapine—HTR2C—GPCR ligand binding—CXCL11—nasal cavity cancer	0.011	0.011	CbGpPWpGaD
Mirtazapine—ADRA2C—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0107	0.0107	CbGpPWpGaD
Mirtazapine—DRD2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00975	0.00975	CbGpPWpGaD
Mirtazapine—HTR2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00959	0.00959	CbGpPWpGaD
Mirtazapine—HRH1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00957	0.00957	CbGpPWpGaD
Mirtazapine—ADRA1A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00939	0.00939	CbGpPWpGaD
Mirtazapine—HRH3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00878	0.00878	CbGpPWpGaD
Mirtazapine—ADRA2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00873	0.00873	CbGpPWpGaD
Mirtazapine—OPRK1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0086	0.0086	CbGpPWpGaD
Mirtazapine—HTR7—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00847	0.00847	CbGpPWpGaD
Mirtazapine—DRD4—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00811	0.00811	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00781	0.00781	CbGpPWpGaD
Mirtazapine—HTR2B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00774	0.00774	CbGpPWpGaD
Mirtazapine—HTR7—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00769	0.00769	CbGpPWpGaD
Mirtazapine—DRD4—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00736	0.00736	CbGpPWpGaD
Mirtazapine—DRD3—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0072	0.0072	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00703	0.00703	CbGpPWpGaD
Mirtazapine—ADRB1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00656	0.00656	CbGpPWpGaD
Mirtazapine—DRD3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00654	0.00654	CbGpPWpGaD
Mirtazapine—ADRB2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00642	0.00642	CbGpPWpGaD
Mirtazapine—HTR1A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00628	0.00628	CbGpPWpGaD
Mirtazapine—HTR2C—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00624	0.00624	CbGpPWpGaD
Mirtazapine—ADRA2C—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00607	0.00607	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00596	0.00596	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00583	0.00583	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0057	0.0057	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00567	0.00567	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00551	0.00551	CbGpPWpGaD
Mirtazapine—DRD2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00551	0.00551	CbGpPWpGaD
Mirtazapine—HTR2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00542	0.00542	CbGpPWpGaD
Mirtazapine—HRH1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00541	0.00541	CbGpPWpGaD
Mirtazapine—ADRA1A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00531	0.00531	CbGpPWpGaD
Mirtazapine—HRH3—Signaling Pathways—FRS2—nasal cavity cancer	0.00518	0.00518	CbGpPWpGaD
Mirtazapine—DRD2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.005	0.005	CbGpPWpGaD
Mirtazapine—ADRA2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00493	0.00493	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00492	0.00492	CbGpPWpGaD
Mirtazapine—HRH1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00491	0.00491	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00482	0.00482	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00461	0.00461	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—CXCL11—nasal cavity cancer	0.00454	0.00454	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00448	0.00448	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00435	0.00435	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00415	0.00415	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00386	0.00386	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00352	0.00352	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00344	0.00344	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00337	0.00337	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—CXCL11—nasal cavity cancer	0.00335	0.00335	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—CXCL11—nasal cavity cancer	0.00326	0.00326	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00296	0.00296	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00291	0.00291	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—CXCL11—nasal cavity cancer	0.0029	0.0029	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00285	0.00285	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—FRS2—nasal cavity cancer	0.00272	0.00272	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—FRS2—nasal cavity cancer	0.00268	0.00268	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00265	0.00265	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—FRS2—nasal cavity cancer	0.00256	0.00256	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—FRS2—nasal cavity cancer	0.00245	0.00245	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—FRS2—nasal cavity cancer	0.00228	0.00228	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—FRS2—nasal cavity cancer	0.00207	0.00207	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—FRS2—nasal cavity cancer	0.00203	0.00203	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—FRS2—nasal cavity cancer	0.00198	0.00198	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—FRS2—nasal cavity cancer	0.00197	0.00197	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—FRS2—nasal cavity cancer	0.00192	0.00192	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—FRS2—nasal cavity cancer	0.00174	0.00174	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—FRS2—nasal cavity cancer	0.00171	0.00171	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—FRS2—nasal cavity cancer	0.00171	0.00171	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—FRS2—nasal cavity cancer	0.00168	0.00168	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—FRS2—nasal cavity cancer	0.00156	0.00156	CbGpPWpGaD
